The effect of particle size on dissolution rate of fast dissolving oral film containing diclofenac sodium

Authors

  • Fitrianti Darusman Universitas Islam Bandung
  • Nyayu Ista Yulita Universitas Islam Bandung
  • Gita Cahya Eka Darma Universitas Islam Bandung

DOI:

https://doi.org/10.12928/pharmaciana.v10i2.15988

Keywords:

diclofenac sodium, nanoparticle, ionic gelation, fast dissolving oral film, dissolution rate

Abstract

Diclofenac sodium is a Non-Steroidal Anti Inflammatory Drugs that if being taken orally have the side effects of peptic ulcers and undergone the first pass metabolism, and also included in the Biopharmaceutics Classification System class 2 which resulted in the low rate of dissolution. This study aims to determine the influence of particle size reduction on the dissolution rate of diclofenac sodium in the form of an FDOF dosage. The formation of diclofenac sodium nanoparticles is carried out by ionic gelation method using chitosan and sodium tripolyphosphate as a crosslinker in various ratios characterized by Particle Size Analyzer and Scanning Electron Microscopy, then it is incorporated into the form of an FDOF that were prepared by solvent casting method at a dose of 12.5 mg using variations concentration of SSG as superdisintegrant and PEG 400 as plasticizer. From the research results, diclofenac sodium nanoparticles are formed in the ratio of chitosan-sodium tripolyphosphate 6:1, have a size of 804 nm and spherical-shaped. The best FDOF dosage formula is F8 containing HPMC E5 LV 35% as the film forming agent, SSG 8% as superdisintegrant and PEG 400 10% as plasticizer.  FDOF formula containing diclofenac sodium nanoparticles has a slightly bitter taste, disintegration time less than one minute, surface pH around 7 (neutral), drug content that meets the requirements of the range of determination which is 93.24 ± 0.96, the cumulative amount of drug dissolved in the 28th minute is higher by 88.45% compared to FDOF containing diclofenac sodium raw material, which is only 70.0%.

References

Adeyeye, C. M., Li, P., & Chemistry, P. (1990). Diclofenac Sodium: Analytical Profiles of Drug Substances, Florey, K., 19, 123–144.

Anonymous. (2014). Farmakope Indonesia V. Indonesia: BPOM RI.

Anonymous. (2017). Combined Index to USP 41 and NF 36, 1–5, 1–72.

Bhumkar, D. R., & Pokharkar, V. B. (2006). Studies on Effect of pH on Cross-linking of Chitosan With Sodium Tripolyphosphate : A Technical Note, 7(2), 2–7.

Buzea, C., Blandino, I. I. P., & Robbie, K. (2007). Nanomaterials and nanoparticles : Sources and toxicity, 2(4), 1–103.

Davies, T. F., & Amino, N. (1993). A new classification for human autoimmune thyroid disease. Thyroid (Vol. 3). https://doi.org/10.1089/thy.1993.3.331

Ghorwade, V., Patil, A., Patil, S., Ikkurthi, K., Inuganti, K. S., & Porandla, V. (2011). Formulation and evaluation of Montelukast sodium fast dissolving films by using Gelatin as a film base. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 2(3), 880–888.

Irfan, M., Rabel, S., Bukhtar, Q., Imran, M., Jabeen, F., & Khan, A. (2016). Orally disintegrating films : A modern expansion in drug delivery system. Saudi Pharmaceutical Journal, 24(5), 537–546. https://doi.org/10.1016/j.jsps.2015.02.024

Kalyan, S., & Bansal, M. (2012). Recent Trends in the Development of Oral dissolving Film, 4(2), 725–733.

Karam, R. (2015). Biowaivers : criteria and requirements prepared by Dr . Mazen Kurdi, 1–11.

Katzung, B. G., Masters, S. B., & Trevor, A. (2012). Basic dan Clinical Pharmacology (Vol. 12). https://doi.org/10.1016/S0065-7743(08)61545-6

Mohanraj, V. J., & Chen, Y. (2007). Nanoparticles - A review. Tropical Journal of Pharmaceutical Research, 5(1), 561–573. https://doi.org/10.4314/tjpr.v5i1.14634

MS, A., & C, V. (2016). Formulation and evaluation of fast dissolving oral films of diazepam. Journal of Pharmacovigilance, 4(3), 1–5. https://doi.org/10.4172/2329-6887.1000210

Nagarajan, E., Shanmugasundaram, P., Ravichandiran, V., Vijayalakshmi, A., Senthilnathan, B., & Masilamani, K. (2015). Development and Evaluation of Chitosan Based Polymeric Nanoparticles of an Antiulcer Drug Lansoprazole, 5(4), 20–25. https://doi.org/10.7324/JAPS.2015.50404

Patravale, V. B., Date, A. A., & Kulkarni, R. M. (2004). Nanosuspensions : a promising drug delivery strategy, (1992), 827–840. https://doi.org/10.1211/0022357023691

Ruíz, A. A. B. (2015). Nanoparticle Technology for Drug Delivery, 3(2), 54–67.

Sweetman, S. C. (2009). Martindale The Complete Drug Reference (Vol. 53). https://doi.org/10.1017/CBO9781107415324.004

Wagh, M. P., & Patel, J. S. (2010). Biopharmaceutical classification system: Scientific basis for biowaiver extensions. International Journal of Pharmacy and Pharmaceutical Sciences, 2(1), 12–19.

Yeo, Y., & Kinam, P. (2007). Recent Advances in Microencapsulation Technology. Encyclopedia of Pharmaceutical Technology, 2315–2327. https://doi.org/10.1081/E-EPT-120028567

Downloads

Published

2020-07-29

Issue

Vol. 10 No. 2 (2020): Pharmaciana

Section

Pharmaceutics and Pharmaceutical Technology

License

Authors who publish with Pharmaciana agree to the following terms:

  1. Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.